CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 77 enrolled
Drug / intervention
Sofosbuvir/Velpatasvir/Voxilaprevirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02745535
NCT02745535Phase 2Completed
CompareCT.gov

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

University of Maryland, Baltimore·interventional·Posted Apr 20, 2016·Updated Mar 10, 2022

In Brief

A Phase 2 clinical trial evaluating Sofosbuvir/Velpatasvir/Voxilaprevir for Chronic Hepatitis C. Completed, enrolled 77 participants across 1 site.

Detailed Summary

This study will evaluate the safety, tolerability, and efficacy of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C infection who have failed to eradicate hepatitis C despite previous combination directly acting antiviral therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesUnited States
CollaboratorsUnity Health Care, Inc., Gilead Sciences

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 20, 2016
Enrollment StartMay 1, 2016
Primary CompletionOct 24, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.2 years ago

Interventions

Sofosbuvir/Velpatasvir/Voxilaprevirdrug